SGFG
AUPH icon

Silver Grove Financial Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Silver Grove Financial Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51 Buy
+3
New +$48 ﹤0.01% 2396

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silver Grove Financial Group's AUPH Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 3 shares worth $51. The stake represents ﹤0.01% of the portfolio and ranks #2396 among its holdings.

281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Silver Grove Financial Group held 3 shares of Aurinia Pharmaceuticals worth $51 as of Q2 2026.
  • Aurinia Pharmaceuticals was a new Silver Grove Financial Group position in Q2 2026.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2396 holding.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.